Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

Science 324 (5933): 1400-1401

Copyright © 2009 by the American Association for the Advancement of Science

Cancer

Breaching the Cancer Fortress

Peter Olson, and Douglas Hanahan

The predominant and invariably lethal form of pancreatic cancer—ductal adenocarcinoma—is characterized by an enveloping fibrotic stroma of excessive connective tissue and cells that forges rock-hard tumors. These tumors are refractory to essentially all therapies; gemcitabine, the standard-of-care chemotherapeutic drug, extends survival by only a few weeks. It has long been surmised that these pathological and clinical features are interconnected. On page 1457 in this issue, Olive et al. (1) confirm this notion, showing that cancer-associated fibroblasts in pancreatic ductal adenocarcinoma are responsible for a poorly vascularized architecture that imposes a barrier to drug delivery. Removing these fibroblasts stimulated the formation of new blood vessels (angiogenesis), improved drug delivery, and extended life span in a de novo mouse model of the disease. This study defines biophysical properties endowed by the tumor microenvironment that contribute to its therapeutic intractability and raises new questions about the role of the microenvironment in the development of this uncontrollable cancer.

Comprehensive Cancer Center, Diabetes Center, and Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94143–0534, USA.

E-mail: polson{at}diabetes.ucsf.edu; dh{at}ucsf.edu


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Genome-wide association study of survival in patients with pancreatic adenocarcinoma.
C. Wu, P. Kraft, R. Stolzenberg-Solomon, E. Steplowski, M. Brotzman, M. Xu, P. Mudgal, L. Amundadottir, A. A. Arslan, H. B. Bueno-de-Mesquita, et al. (2014)
Gut 63, 152-160
   Abstract »    Full Text »    PDF »
Current concepts and novel targets in advanced pancreatic cancer.
P. Michl and T. M. Gress (2013)
Gut 62, 317-326
   Abstract »    Full Text »    PDF »
Three-Dimensional Collagen I Promotes Gemcitabine Resistance in Pancreatic Cancer through MT1-MMP-Mediated Expression of HMGA2.
S. Dangi-Garimella, S. B. Krantz, M. R. Barron, M. A. Shields, M. J. Heiferman, P. J. Grippo, D. J. Bentrem, and H. G. Munshi (2011)
Cancer Res. 71, 1019-1028
   Abstract »    Full Text »    PDF »
Forkhead Box F1 Regulates Tumor-Promoting Properties of Cancer-Associated Fibroblasts in Lung Cancer.
R. A. Saito, P. Micke, J. Paulsson, M. Augsten, C. Pena, P. Jonsson, J. Botling, K. Edlund, L. Johansson, P. Carlsson, et al. (2010)
Cancer Res. 70, 2644-2654
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882